Wednesday, 26 August 2026European Markets

LUMIBIRD Stock Bullish Momentum With A 9.22% Rise On Tuesday

Loading stream...

(vianews) - the market ended the session with lumibird (lbird.pa) jumping 9.22% to €15.40 on tuesday, following the last session's upward trend. cac 40 dropped 0.16% to €7,406.01, after three sequential sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

about lumibird

lumibird sa designs, manufactures, and sells various lasers for the scientific, industrial, and medical applications worldwide. it operates in two segments, photonics and medical. the company offers solid-state and diode lasers, fiber lasers, fiber lasers/amplifiers and components, laser rangefinder and lidar wind doppler lidar, medical and ophthalmological equipment. its products are used in various applications, such as industrial and scientific, defense and space, and lidar sensors. the company was incorporated in 1970 and is headquartered in lannion, france.

earnings per share

as for profitability, lumibird has a trailing twelve months eps of €0.45.

pe ratio

lumibird has a trailing twelve months price to earnings ratio of 34.22. meaning, the purchaser of the share is investing €34.22 for every euro of annual earnings.

volatility

lumibird's last week, last month's, and last quarter's current intraday variation average was 1.72%, 0.23%, and 1.73%.

lumibird's highest amplitude of average volatility was 1.72% (last week), 2.13% (last month), and 1.73% (last quarter).

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, lumibird's stock is considered to be oversold (<=20).

more news about lumibird (lbird.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com